<?xml version='1.0' encoding='utf-8'?>
<document id="18574557"><sentence text="Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors."><entity charOffset="30-42" id="DDI-PubMed.18574557.s1.e0" text="ketoconazole" /><entity charOffset="111-132" id="DDI-PubMed.18574557.s1.e1" text="motesanib diphosphate" /><pair ddi="false" e1="DDI-PubMed.18574557.s1.e0" e2="DDI-PubMed.18574557.s1.e0" /><pair ddi="false" e1="DDI-PubMed.18574557.s1.e0" e2="DDI-PubMed.18574557.s1.e1" /></sentence><sentence text="Motesanib diphosphate is a novel angiogenesis inhibitor selectively targeting vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor and stem cell factor receptor"><entity charOffset="0-21" id="DDI-PubMed.18574557.s2.e0" text="Motesanib diphosphate" /></sentence><sentence text=" The purpose of this phase 1b, drug-drug interaction study was to investigate the effect of ketoconazole, a strong inhibitor of the cytochrome P450 3A4 isoenzyme, on the pharmacokinetics and tolerability of motesanib diphosphate"><entity charOffset="92-104" id="DDI-PubMed.18574557.s3.e0" text="ketoconazole" /><entity charOffset="207-228" id="DDI-PubMed.18574557.s3.e1" text="motesanib diphosphate" /><pair ddi="false" e1="DDI-PubMed.18574557.s3.e0" e2="DDI-PubMed.18574557.s3.e0" /><pair ddi="false" e1="DDI-PubMed.18574557.s3.e0" e2="DDI-PubMed.18574557.s3.e1" /></sentence><sentence text=" Fourteen patients with advanced solid tumors refractory to standard treatment were enrolled and received motesanib diphosphate 50 mg once daily from day 1 through 15"><entity charOffset="106-127" id="DDI-PubMed.18574557.s4.e0" text="motesanib diphosphate" /></sentence><sentence text=" Patients were randomized to receive a single oral dose of ketoconazole 400 mg either on day 8 (Sequence 1; n = 7) or day 15 (Sequence 2; n = 7), while pharmacokinetic samples were collected"><entity charOffset="59-71" id="DDI-PubMed.18574557.s5.e0" text="ketoconazole" /></sentence><sentence text=" After completion of this part (day 16), 13 patients received an escalated once-daily dose of motesanib diphosphate 125 mg"><entity charOffset="94-115" id="DDI-PubMed.18574557.s6.e0" text="motesanib diphosphate" /></sentence><sentence text=" Evaluable pharmacokinetic data (n = 12) suggest that ketoconazole modestly increased motesanib exposure"><entity charOffset="54-66" id="DDI-PubMed.18574557.s7.e0" text="ketoconazole" /><entity charOffset="86-95" id="DDI-PubMed.18574557.s7.e1" text="motesanib" /><pair ddi="false" e1="DDI-PubMed.18574557.s7.e0" e2="DDI-PubMed.18574557.s7.e0" /><pair ddi="false" e1="DDI-PubMed.18574557.s7.e0" e2="DDI-PubMed.18574557.s7.e1" /></sentence><sentence text=" The motesanib area under the concentration-time curve (AUC) from 0 to 24 h increased by 86% (90% CI, 1"><entity charOffset="5-14" id="DDI-PubMed.18574557.s8.e0" text="motesanib" /><entity charOffset="98-100" id="DDI-PubMed.18574557.s8.e1" text="CI" /><pair ddi="false" e1="DDI-PubMed.18574557.s8.e0" e2="DDI-PubMed.18574557.s8.e0" /><pair ddi="false" e1="DDI-PubMed.18574557.s8.e0" e2="DDI-PubMed.18574557.s8.e1" /></sentence><sentence text="50-2" /><sentence text="29; P &lt; 0" /><sentence text="001) and the maximum plasma concentration (C (max)) by 35% (90% CI, 1"><entity charOffset="64-66" id="DDI-PubMed.18574557.s11.e0" text="CI" /></sentence><sentence text="12-1" /><sentence text="64; P = 0" /><sentence text="02), compared with motesanib diphosphate administration alone"><entity charOffset="19-40" id="DDI-PubMed.18574557.s14.e0" text="motesanib diphosphate" /></sentence><sentence text=" The tolerability profile (with or without ketoconazole coadministration) was consistent with that from other motesanib diphosphate monotherapy studies"><entity charOffset="43-55" id="DDI-PubMed.18574557.s15.e0" text="ketoconazole" /><entity charOffset="110-131" id="DDI-PubMed.18574557.s15.e1" text="motesanib diphosphate" /><pair ddi="false" e1="DDI-PubMed.18574557.s15.e0" e2="DDI-PubMed.18574557.s15.e0" /><pair ddi="false" e1="DDI-PubMed.18574557.s15.e0" e2="DDI-PubMed.18574557.s15.e1" /></sentence><sentence text=" Treatment-related adverse events were mild to moderate and commonly included fatigue (50% of patients), hypertension (43%), diarrhea (21%), dizziness (14%), paresthesia (14%), and vomiting (14%)" /><sentence text=" Hypertension was the most common related grade 3 event (21%)" /><sentence text=" No grade 4 or 5 treatment-related adverse events occurred" /><sentence text="" /></document>